A complete response (CR) after treatment is usually associated with a longer event-free survival, a longer duration of response, and a longer survival for patients with non-Hodgkin's lymphoma (NHL), but very seldom with a good partial response (PR); cure has only been described in CR patients after the first line of treatment. Thus, the main objective for the treatment must be to achieve a CR in the majority of the patients. Some exceptions have been observed: long time to progression or long time to next treatment in some PR patients with indolent lymphomas; a good PR may be considered for elderly patients, particularly those with an indolent lymphoma; patients with an indolent lymphoma and no adverse prognostic factors may have a delayed treatment. However, defining a CR may be difficult in some patients, particularly those with an aggressive lymphoma and a large tumor mass at diagnosis, who seem to respond very well to the treatment, with the disappearance of all clinical or biological abnormalities but with persistence of some radiological abnormalities. In different retrospective analyses, the percentage of patients with good PR, defined as the persistence of any radiological abnormalities, who did not progress, and their ultimate time to progression, were not different from those observed in patients with a true CR [1, 2] . Recently, international experts gathered to refine the definition of the different events that may occur in lymphoma patients, particularly the criteria defining a complete response and the other responses [3] . Because of this uncertainty in the definition of CR, a new category of response, CRu, was created to reflect the unknown significance of persisting radiological abnormalities in patients who seem otherwise in CR.
Whatever the terms used to describe the response to treatment, patients in CR cannot be considered cured and 30%-60% of them will relapse, depending on the type of lymphoma and its initial characteristics. A similar percentage of patients with persisting CT scan abnormalities will also relapse [1] . Some studies reported that the risk of progression was not greater in the site of persisting radiological abnormalities than in other parts of the body [2] . The problem is particularly important for patients with the so-called aggressive lymphomas, diffuse large B-cell lymphomas and peripheral T-cell lymphomas. In fact, in our experience, almost all indolent patients with persisting radiological abnormalities have progressed and it is the same for patients with Burkitt's or lymphoblastic lymphomas. In patients with aggressive NHL, CT scan after completion of the treatment shows abnormal images in 40% to 50% of those with initial large tumor masses, even if these patients seem to respond very well to the treatment, with normalization of all clinical and biological abnormalities. When peripheral lymph nodes persist, an aspiration or a biopsy of this mass frequently shows the persistence of lymphoma cells. In these patients or those with persisting bone marrow infiltration, the staging of the response is easy and they may only be qualified as in PR. However, for patients with persisting abdominal or thoracic abnormalities, a new biopsy is not recommended because of the risk of the procedure and the necessity to completely remove all abnormality in order to be able to conclude that in fact no lymphoma cells remain. A cytological examination of aspirates of the abnormal mass is not sufficient to conclude in favor of CR if it does not show any lymphoma cells but it may be indicative of a PR if the lymphoma cells are present.
Magnetic resonance imaging did not prove to be more useful than CT scan for predicting the nature of such residual masses [4, 5] . Some centers have proposed utilization of 67 gallium scanning [6] [7] [8] to assess remission and the nature of residual masses. The use of 67 Ga SPECT (single photon emission computed tomography) is particularly efficacious for evaluating the mediastinal masses but is of little use in the abdomen because of the hepatic uptake and excretion into the bowel. Moreover, 67 Ga scintigraphy should always be performed before treatment to determine whether the patient has a gallium fixing tumor and whether the absence of fixation after the treatment corresponds to a residual mass [9] . This is a restrictive parameter for the routine application of 67 Ga scintigraphy in the evaluation of patients with large mediastinal masses. It was described that around 80% or less of the patients with a mediastinal lymphoma fixed 67 Ga and recommended that 67 Ga scintigraphy be performed before and after completion of the treatment to avert incorrect conclusions in patients with persisting masses whose tumors did not fix 67 Ga [8] . A nonspecific fixation has been described in young patients with thymic rebound after chemotherapy [10] or nonspecific hilar activity [11] which could lead to false conclusions.
Positron emission tomography (PET) with 18-fluorodeoxyglucose offered another functional imaging modality. The fixation of 18-fluoro-deoxyglucose (FDG) by malignant cells reflects an increase of the glycolytic activity of tumor cells [12] . FDG has been shown to concentrate preferentially in metabolically active malignant tissues, particularly lymphomas. During the last five years, preliminary reports have shown that PET scanning may allow a more accurate staging of the disease before treatment and the differentiation of tumor masses with persisting active lymphoma cells from necrotic inactive masses [13] [14] [15] [16] [17] . In a small series of 11 patients, Romer suggested that a PET scan analysis after 2 courses of chemotherapy may be sufficient to differentiate the patients who can be cured from those with much more resistant disease in whom more intensive chemotherapy is required [18] .
In this issue of Annals of Oncology, Zinzani et al. report the potential of PET scan in the identification of patients with active lymphoma among those with persisting radiological mass at the end of the treatment in Hodgkin's disease (HD) and NHL. In this study [19] , including 44 patients with HD or aggressive abdominal NHL, 40% of those with bulky tumor underwent CT scan and PET scan at the end of the scheduled treatment. The results of these examinations were compared in relapsing patients or those who continued in CR with a median follow-up of 18 months. Thus, only early relapses were identified. However, the results were impressive: 37 patients had a CT scan abnormality, and 16 of them a positive PET scan; all these 16 patients relapsed, the majority of them during the first year after completion of the treatment and in the positive PET scan site. Conversely, only one patient with an abnormal CT scan and a negative PET scan relapsed. Jerusalem et al. recently reported a positive predictive value of 100% for the PET scan (6 of 6 positive patients relapsed) compared to 42% for CT scan (10 of 24 positive patients relapsed) [20] . In this study too, patients with a positive PET scan had rapid relapses after the completion of the treatment. The negative predictive value was 83% for the PET scan and 87% for the CT scan (40 of 48 and 26 of 30 patients remained disease-free, respectively). The patients who relapsed without a PET scan fixation relapsed later than those with a PET scan fixation. A higher risk of relapse was observed in patients with negative PET scan but a residual mass on CTscan [20] .
In spite of the short follow-up in these studies, they all confirm that PET scan is the best way to identify patients with a poor response to treatment and a very high risk of early relapse. However, some questions were not answered by this study: when is the best time to evaluate the patients, during or after the treatment? Is the PET scan more valuable for patients with bulky tumors or in all cases? Are the results identical in HD, indolent or aggressive lymphomas? Should the PET scan be performed in all of the patients or only in those with an abnormal CT scan? What is the percentage of late relapses in patients with negative PET scan? What will CT scan's role be in the evaluation of treatment results in the future? Because of the much higher cost of the PET scan, it will not be possible to repeat both scans several times. The more interesting question not settled by this study is: what is the potential for curing a patient with a positive PET scan if the treatment is intensified at this time? As a non-specific fixation has also been described with PET scan [21] , the frequency of false positive scans needs to be determined.
In conclusion, PET scan seems a very valuable tool for identifying patients who do not respond well to the proposed treatment. However, larger studies are needed to correlate the results of PET scans with the initial characteristics of the tumor and to determine the type of patient in whom its performance will yield the most interesting data. Another type of study will be to modify and /or intensify the treatment of patients with positive PET scan to determine whether this test makes it possible to identify high-risk patients before they become refractory to any treatment. Another interesting point to analyze will be the reasons and modalities of relapse in patients with negative PET scan. This may reveal as-yet unknown mechanisms of refractoriness to chemotherapy.
Finally, PET scan is still an expansive examination and the merit of this new technique will have to be compared with CTscan in terms of cost. Should it really allow identification of patients at risk for early relapse, and if a modification of the treatment at this time could bring about a cure or a very long survival, PET machines will have to be largely implanted and priority will have to be designed for that. In such case, one may hope that its development will mean a decrease in its cost. However, if the implications of a positive result are not addressed or if the sensitivity and specificity of the examination are not confirmed in large studies, this technique will be reserved for wealthy countries or wealthy centers.
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